Aarti Drugs Limited

AARTIDRUGS

INE767A01016

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 02:33:22 11/07/2025 pm IST			5-day change	1st Jan Change
477.00 ^INR	-0.02%		-1.42%	+3.55%

07/05	Aarti Drugs Consolidated Net Profit Jumps in Fiscal Q4	MT
07/05	Aarti Drugs Limited, Q4 2025 Earnings Call, May 07, 2025

Aarti Drugs March-Quarter Consol Net Profit 628.6 Mln Rupees

Published on 06/05/2025 at 16:26

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Aarti Drugs Limited

Aarti Drugs Consolidated Net Profit Jumps in Fiscal Q4	07/05	MT
Aarti Drugs Limited, Q4 2025 Earnings Call, May 07, 2025	07/05
Aarti Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2025	06/05	CI
Aarti Drugs March-Quarter Consol Net Profit 628.6 Mln Rupees	06/05	RE
Aarti Drugs Receives Administrative Warning Letter From SEBI	07/03	RE
Aarti Drugs Says SEBI Issues Administrative Warning To Co's Compliance Officer, Company Secretary	06/03	RE
US FDA Removes Import Alert on Aarti Drugs Limited's API Manufacturing Facility	14/02	CI
Aarti Drugs Limited Receives an Order Refer with GST DRC-07 from the CGST & C.Ex. Authority	07/02	CI
Aarti Drugs To Acquire 26.25% Equity In Pro-ZEAL Green Power Nine	03/02	RE
Aarti Drugs Limited, Q3 2025 Earnings Call, Jan 30, 2025	30/01
Pinnacle Life Science Pvt. Ltd announced that it expects to receive INR 250 million in funding from Aarti Drugs Limited	29/01	CI
Aarti Drugs Limited Receives Order in Form DRC-22 from Office of Joint Commissioner of State Tax, Investigation-B, Mumbai	28/01	CI
Aarti Drugs to Acquire 26% Stake in Renewable Energy Company	10/01	MT
Pro-Zeal Green Power Six Private Limited announced that it expects to receive INR 0.63 million in funding from Aarti Drugs Limited	09/01	CI
Aarti Drugs Restores Manufacturing Actitvity at Tarapur, India Unit	18/11	MT
Aarti Drugs Limited Announces Restoration of Manufacturing Process of Particular Product At T-150 Unit	16/11	CI
Aarti Drugs Limited, Q2 2025 Earnings Call, Oct 25, 2024	25/24/25
Tranche Update on Aarti Drugs Limited's Equity Buyback Plan announced on August 26, 2024.	26/24/26	CI
Aarti Drugs Limited Announces Conduction of Inspection by United States Food and Drug Administration	25/24/25	CI
Aarti Drugs Limited's Equity Buyback announced on August 26, 2024 has closed with 665,000 shares, representing 0.72% for INR 598.5 million.	19/24/19	CI
Aarti Drugs Gets Board Nod to Buy Back Shares of Up to INR598.5 Million	26/24/26	MT
Aarti Drugs Limited announces an Equity Buyback for 665,000 shares, representing 0.72% for INR 598.5 million.	26/24/26	CI
Aarti Drugs Limited authorizes a Buyback Plan.	26/24/26	CI
Aarti Drugs Limited's Board intends to launch an Equity Buyback on August 26, 2024.	21/24/21	CI
Aarti Drugs Limited Receives Show Cause Notice from Central Goods and Service Tax & Central Excise	03/24/03	CI

Aarti Drugs Limited is an India-based company, which is engaged in manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include iprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole, ofloxacin, and others. Its specialty chemicals includes benzene sulphonyl chloride, methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include alpha lipoic acid, itraconazole, ticagrelor, and sitagliptin. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, and Pinnacle Chile SPA.

Employees

1,064

Sector

Pharmaceuticals

Calendar

24/07 - Q1 2026 Earnings Release (Projected)

More about the company